Saturday, 31 October 2026European Markets

SHURGARD And GALIMMO Have A High Dividend Yield And Return On Equity In The Real Estate Services Industry.

Loading stream...

(vianews) - shurgard (shur.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate services industry.

financial asset price forward dividend yield return on equity
shurgard (shur.br) €41.22 2.74% 17.85%
galimmo (galim.pa) €15.20 2.35% 2.01%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. shurgard (shur.br)

2.74% forward dividend yield and 17.85% return on equity

shurgard self storage ltd, together with its subsidiaries, engages in the acquisition, development, and operation of self-storage facilities for business and personal use. the company also offers various ancillary services at its self-storage facilities consisting of sale of storage products and provision of protection through an independent insurance company for customers' stored goods. the company owns and/or operates 267 self-storage facilities and approximately 1.4 million net rentable square meters in france, the netherlands, the united kingdom, sweden, germany, belgium, and denmark. shurgard self storage ltd was founded in 1995 and is based in luxembourg, luxembourg.

earnings per share

as for profitability, shurgard has a trailing twelve months eps of €5.89.

pe ratio

shurgard has a trailing twelve months price to earnings ratio of 7. meaning, the purchaser of the share is investing €7 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.85%.

sales growth

shurgard's sales growth is negative 2.2% for the current quarter and 2.6% for the next.

volatility

shurgard's last week, last month's, and last quarter's current intraday variation average was a negative 0.99%, a positive 0.03%, and a positive 1.63%.

shurgard's highest amplitude of average volatility was 0.99% (last week), 1.35% (last month), and 1.63% (last quarter).

yearly top and bottom value

shurgard's stock is valued at €41.22 at 16:40 est, way under its 52-week high of €49.50 and way higher than its 52-week low of €34.01.

more news about shurgard.

2. galimmo (galim.pa)

2.35% forward dividend yield and 2.01% return on equity

galimmo sca operates as a real estate company in europe. as of december 31, 2021, it owned and managed 52 shopping malls. galimmo sca was formerly known as c&co sca and changed its name to galimmo sca in september 2016. the company was incorporated in 1902 and is headquartered in paris, france. galimmo sca is a subsidiary of galimmo real estate.

earnings per share

as for profitability, galimmo has a trailing twelve months eps of €0.29.

pe ratio

galimmo has a trailing twelve months price to earnings ratio of 52.41. meaning, the purchaser of the share is investing €52.41 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.01%.

yearly top and bottom value

galimmo's stock is valued at €15.20 at 16:40 est, under its 52-week high of €15.60 and way above its 52-week low of €12.90.

revenue growth

year-on-year quarterly revenue growth declined by 1%, now sitting on 46.39m for the twelve trailing months.

more news about galimmo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com